Credit: Vertex. A new oral granule formulation has been approved and is supplied in morning and evening unit-dose packets. The approval was based on data from a 24-week open-label, two-part phase 3 ...

The cystic fibrosis drug Trikafta helps roughly 90 percent of patients, while the other 10 percent are still waiting for their "miracle drug." (Randy Vazquez/Globe Staff) The cystic fibrosis drug ...

Vertex Pharmaceuticals Incorporated is performing well in the Cystic Fibrosis market with its drug Trikafta, leading to an increase in full-year 2023 guidance. The company has two expansion ...

CHANNAHON, Ill. (WLS) -- Brandon Wolfe enjoys spending quality time with his family. Playing with his young sons wasn't always easy, but he has a lot more energy to play after testing a new drug to ...

The FDA expanded the indication for elexacaftor, tezacaftor, and ivacaftor (Trikafta) in cystic fibrosis to include even younger children, maker Vertex Pharmaceuticals announced. FDA approval for this ...

Colorado’s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn’t qualify as “unaffordable,” based on the drug’s benefits ...

WASHINGTON (CBS Local)-- A treatment that could benefit 90 percent of cystic fibrosis patients was approved Monday by the U.S. Food and Drug Administration. The FDA approved a combination of three ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented in ...

After a year of treatment with ETI, chronic rhinosinusitis was improved as measured by the Lund-Mackay sinus CT scoring system (decreasing from 5.8 [IQR 5.0-7.0] to 3.3 points [IQR 2.6-4.2]) and the ...

MONTGOMERY, Ala. (WSFA) - A new drug used to treat cystic fibrosis is showing promising results in patients across the country. Elexacaftor/tezacaftor/ivacaftor, sold ...